Lanadelumab in Bradykinin Angioedema

Launched by UNIVERSITY HOSPITAL, GRENOBLE · Oct 16, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a medication called lanadelumab to see how well it works in treating bradykinin angioedema, a condition that causes sudden swelling in various parts of the body. The trial is taking place at multiple centers and is currently looking for participants. To be eligible, you need to be over 18 years old and either have hereditary (passed down through families) or acquired angioedema. Additionally, you should be undergoing treatment with lanadelumab and have your biological tests done at the specified laboratory.

If you decide to participate, you will need to provide your consent, and your medical team will monitor your progress throughout the study. This trial does not allow individuals who are pregnant, nursing, or under guardianship to participate. The goal is to gather important information about how effective lanadelumab is, which can eventually help improve treatment options for patients with this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male/female \>18 years old
• • Patient with hereditary or acquired angioedema
• • Patient treated by lanadelumab
• • Patient whose the biological explorations have been carried out or will be carried out at Laboratory of Immunology of CHUGA
• • Informed consent is obtained from the participant
• Exclusion Criteria:
• • Absence of biological material at T0 and M3 (stored for routine analysis)
• • Person under guardianship or curatorship
• • Female who is pregnant, nursing